Literature DB >> 15841888

Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty.

Andrew Briggs.   

Abstract

Mesh：

Year:  2005        PMID： 15841888     DOI： 10.1111/j.1524-4733.2005.08101.x

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  47 in total

1.  Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Authors:  Javier Soto
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  A study of pre-decision evaluation using influence diagram: an estimation of the benefits of influenza vaccination.

Authors:  Fan Wu; Pei-Ran Sun; His-Kun Ke; Hsieh-Hong Huang; Yungyen Chiang
Journal:  J Med Syst       Date:  2009-02       Impact factor: 4.460

3.  A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.

Authors:  D Eldon Spackman; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Population-level cost-effectiveness of implementing evidence-based practices into routine care.

Authors:  John C Fortney; Jeffrey M Pyne; James F Burgess
Journal:  Health Serv Res       Date:  2014-10-18       Impact factor: 3.402

5.  Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome.

Authors:  Casey R Tak; Eman Biltaji; Wendy Kohlmann; Luke Maese; Pierre Hainaut; Anita Villani; David Malkin; Catherine M T Sherwin; Diana I Brixner; Joshua D Schiffman
Journal:  Pediatr Blood Cancer       Date:  2019-02-04       Impact factor: 3.167

6.  Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada.

Authors:  William Herring; Isobel Pearson; Molly Purser; Hamid Reza Nakhaipour; Amin Haiderali; Sorrel Wolowacz; Kavisha Jayasundara
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

7.  Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.

Authors:  Santiago Zuluaga-Sanchez; Megan Teynor; Christopher Knight; Robin Thompson; Thomas Lundqvist; Mats Ekelund; Annabelle Forsmark; Adrian D Vickers; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

8.  Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation.

Authors:  Andrew J Spieker; Nicholas Illenberger; Jason A Roy; Nandita Mitra
Journal:  Stat Methods Med Res       Date:  2021-04-07       Impact factor: 3.021

9.  Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.

Authors:  Carlos J Gallego; Caroline S Bennette; Patrick Heagerty; Bryan Comstock; Martha Horike-Pyne; Fuki Hisama; Laura M Amendola; Robin L Bennett; Michael O Dorschner; Peter Tarczy-Hornoch; William M Grady; S Malia Fullerton; Susan B Trinidad; Dean A Regier; Deborah A Nickerson; Wylie Burke; Donald L Patrick; Gail P Jarvik; David L Veenstra
Journal:  Contemp Clin Trials       Date:  2014-07-03       Impact factor: 2.226

10.  Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.

Authors:  T E Delea; K El Ouagari; J Rotter; A Wang; S Kaura; G J Morgan
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.